On Saturday 22 June the Sanniotech Consortium in Benevento will host the event “Bridging the gap between clinical practice and innovation in gastric cancer: the potential of nanoparticles”. The conference will see the participation of experts in the field of medicine and technology, with a focus on new frontiers in the treatment of gastric cancer.
The event represents an extraordinary opportunity for discussion between specialists in oncology medicine, scientific research and advanced technologies. The main objective is to present the latest discoveries and advances in the treatment of gastric cancer, promoting dialogue and collaboration between professionals in the field. The Nanogast project represents an ambitious initiative that promises to revolutionize oncology therapies, improving efficacy and safety thanks to an innovative methodology of targeted release of the drug at the tumor site.
The opening of the conference will be entrusted to Fra Lorenzo Gamos, Superior of the Fatebenefratelli Hospital in Benevento, who will welcome the participants. Subsequently, Piero Porcaro, vice president of Confindustria Benevento with responsibility for Research and Innovation, and Antonio Febbraro, scientific director of Onc, will illustrate the treatment path for patients with gastric cancer.
Pasquale Vito, director of the Department of Science and Technology of the University of Sannio, will explore the impact of precision medicine on solid tumors. Followed by Cristiano Huscher, director of robotic oncology surgery and new technologies at the L. Cobellis nursing home in Vallo della Lucania, who will present the new frontiers of robotic surgery in stomach tumors.
A key moment will then be the presentation of the Nanogast Project by Gaetano Cardinale, president of the Sanniotech consortium, and Serena Voccola, first researcher of the consortium. This project uses Plga nanoparticles as carriers for the monoclonal antibody trastuzumab, offering a targeted and controlled release of the drug directly into the tumor site. This innovation will be fundamental for reducing side effects and increasing the stability of the treatment.
Andrea Cusano, professor of Electronics at the University of Sannio, will talk about the new technologies for human health developed by Cnos. Finally, Angelo Rondine, chief operation officer of MedITech, will illustrate the innovation support offered by their company.
The event represents a unique opportunity for doctors, researchers and healthcare professionals to update and discuss the most recent technological innovations in the treatment of gastric cancer, thus contributing to the advancement of the frontiers of oncology medicine in our territory and to the improvement of the quality of life of patients.
For further information and to participate, you can contact the Sanniotech Consortium at [email protected].
